What is the reimbursement price of dabrafenib in medical insurance?

Dabrafenib is a highly targeted BRAF inhibitor that has been widely used in the treatment of multiple malignant tumors characterized by BRAF V600 mutations. As one of the important representative drugs in the era of precision medicine, dabrafenib was first approved for the treatment of unresectable or metastatic melanoma carrying BRAF V600E mutations. The indication was subsequently expanded to be used in combination with the MEK inhibitor trametinib for the treatment of non-small cell lung cancer (NSCLC) with BRAF V600E or V600K mutations and certain types of thyroid cancer.

This drug inhibits the activity of BRAF protein kinase and blocks the MAPK signaling pathway, thereby inhibiting the growth and spread of tumor cells. Especially in the context of combined medication, its efficacy has been listed as one of the recommended regimens in multiple international clinical guidelines.

In China, the original drug of dabrafenib was introduced by Novartis and is currently sold in two main specifications, namely50 mg × 120 capsules and 75 mg × 120 capsules. Its pricing is in the high range of targeted drugs, and the price per box is often more than 10,000 yuan. Long-term use is a considerable expense for ordinary families. However, with the continuous optimization of the national medical insurance catalog and the improvement of the drug negotiation mechanism, dabrafenib has been officially included in the Chinese medical insurance system for the treatment of patients with specific types of melanoma and non-small cell lung cancer.

According to relevant medical insurance policies, patients who meet the scope of indications and complete registration can enjoy drug reimbursement according to the prescribed proportion. The specific reimbursement amount varies slightly according to regional medical insurance policies and hospital implementation. After medical insurance reimbursement, the actual out-of-pocket price of patients has dropped significantly, and the pressure on drug expenses has been effectively alleviated. However, it is important to note that the scope of use covered by medical insurance is strictly limited. It is currently limited to patients with two types of melanoma andNSCLC, and must meet conditions such as positive BRAF mutation and clear clinical diagnosis.

Reference materials:https://go.drugbank.com/drugs/DB08912